Overall response assessments in patients receiving ibrutinib in the ASPEN study and zanubrutinib in the LTE1 study. ∗CR (n = 2) was assessed by the investigators based on serum IgM and negative immunofixation; they were not confirmed by bone marrow biopsy. MR, minor response.